THE IMPACT OF ANTIPSYCHOTICS ON WEIGHT-GAIN OF PATIENTS WITH MENTAL DISORDERS
DOI:
https://doi.org/10.11603/2411-1597.2016.2.7432Abstract
In this article are examined some of the key issues surrounding weight-gain in individuals suffering from mental disorders. It is showed that Weight gain is a common adverse effect of using anti-psychotic medications, and can be rapid and difficult to control. Weight gain does not seem to be dose dependent within the normal therapeutic range. The effect is worse with clozapine and olanzapine; minimal with aripiprazole and ziprasidone; and intermediate with other antipsychotics, including low-potency First Generation Antipsychotics.
References
Enez Darcin A, Yalcin Cavus S, Dilbaz N, Kaya H, Dogan E. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings. Schizophr Res. 2015 Aug; 166(1-3): 201-6.
Silarova B, Giltay EJ, Van Reedt Dortland A, Van Rossum EF, Hoencamp E, Penninx W, Spijker AT. Metabolic syndrome in patients with bipolar disorder: comparison with major depressive disorder and non-psychiatric controls. J Psychosom Res. 2015 Apr; 78(4):391-8.
Mansur RB, Brietzke E, McIntyre RS. Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 2015 May; 52:89-104.
Nyboe L, Vestergaard CH, Moeller MK, Lund H, Videbech P. Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up. Schizophr Res. 2015 Aug 13.
Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 2013 Feb; 47(2): 197-207.
Stahl SM. Stahl’s Essential Psychopharmacology. Fourth Edition.
Teff KL, Rickels K, Alshehabi E, Rickels MR. Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics. J Clin Psychopharmacol. 2015 Aug 13.
Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005 Jun; 27(5): 289-304.
Edlinger M, Hofer A, Rettenbacher MA, Baumgartner S, Widschwendter CG, Kemmler G, Neco NA, Fleischhacker WW. Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. Schizophr Res. 2009 Sep;113(2-3):246-51. doi: 10.1016/j.schres.2009.06.008.
TS Deepak, BN Raveesh, BM Parashivamurthy, MS Narendra Kumar, Sumanth Mallikarjuna Majgi, and HN Nagesh. Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride. Clin Diagn Res. 2015 Jun; 9(6): FC07–FC10. Published online 2015 Jun 1. doi: 10.7860/JCDR/2015/13007.6066
Komossa K1, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI, Kissling W, Leucht S.Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010 Jan 20;(1): CD006624. doi: 10.1002/14651858.CD006624.pub2.
Coulouvrat c& Dondey-Nouvel L:Safety of amisulpride (Solian (R): a review of 11 clinical studies. Int Clin Psychopharmacol 1999; 14(4): 209-218.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27(2): 596-601.
